Experimental Research Laboratories, Transplantology and Biotechnology Area, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
J Med Virol. 2018 Oct;90(10):1620-1628. doi: 10.1002/jmv.25225. Epub 2018 Jul 10.
Immune correlates of protection against human cytomegalovirus (HCMV) infection are still debated. This study aimed to investigate which arm of the immune response plays a major role in protection against HCMV infection in kidney transplant recipients (n = 40) and heart transplant recipients (n = 12). Overall, patients were divided into 2 groups: one including 37 patients with low viral load (LVL), and the other including 15 patients with high viral load (HVL). All LVL patients resolved the infection spontaneously, whereas HVL patients were all treated with one or more courses of antivirals. In HVL patients, viral DNAemia, which was more than 100 times higher than LVL, appeared and peaked at significantly earlier times, but disappeared much later than in LVL patients. During a 1-year follow-up, all LVL patients had levels of HCMV-specific CD4 (and CD8 ) T cells significantly higher than HVL patients. On the contrary, titers of neutralizing antibodies and enzyme-linked immunosorbent assay-IgG antibodies to gB, gHgLgO, and pentamer gHgLpUL128L were overlapping in the 2 patient groups. In conclusion, while a valid HCMV-specific T-cell response was detected in more than 90% of LVL patients, >90% of HVL patients lacked an adequate T-cell response. Antibody responses did not appear to be associated directly or indirectly with protection.
针对人类巨细胞病毒(HCMV)感染的免疫保护相关性仍存在争议。本研究旨在探讨在肾移植受者(n=40)和心脏移植受者(n=12)中,哪种免疫反应分支在预防 HCMV 感染中起主要作用。总的来说,患者被分为两组:一组包括 37 例病毒载量低(LVL)的患者,另一组包括 15 例病毒载量高(HVL)的患者。所有 LVL 患者均自发性清除感染,而 HVL 患者均接受了一个或多个疗程的抗病毒治疗。在 HVL 患者中,病毒 DNA 血症的水平比 LVL 高 100 多倍,出现和达到峰值的时间明显更早,但消失的时间比 LVL 患者晚得多。在 1 年的随访中,所有 LVL 患者的 HCMV 特异性 CD4(和 CD8)T 细胞水平均显著高于 HVL 患者。相反,中和抗体滴度和酶联免疫吸附试验-IgG 抗体对 gB、gHgLgO 和五聚体 gHgLpUL128L 在两组患者中重叠。总之,在超过 90%的 LVL 患者中检测到有效的 HCMV 特异性 T 细胞反应,而超过 90%的 HVL 患者缺乏充分的 T 细胞反应。抗体反应似乎与保护作用没有直接或间接的关系。